Search

Displaying results 1961 - 1970 of 2854 in total
  1. Drug

    Zuranolone

    go.drugbank.com/drugs/DB15490
    ApprovedInvestigational

    Zuranolone is a neuroactive steroid that acts as a positive allosteric modulator of the GABAA receptors. Unlike other more common GABAA positive allosteric modulators on the market like benzodiazepines, zuranolone can modulate both synap...

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  2. Drug

    Pradefovir

    go.drugbank.com/drugs/DB15550
    Investigational

    Pradefovir is a prodrug of adefovir.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  3. Drug

    Desfesoterodine

    go.drugbank.com/drugs/DB15578
    Investigational

    Desfesoterodine is a metabolite of tolterodine.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2D6 Substrates
  4. Drug

    Cryptotanshinone

    go.drugbank.com/drugs/DB15579
    Experimental

    Categories: Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP2C9 Inhibitors
  5. Drug

    JPC-3210

    go.drugbank.com/drugs/DB15609
    Experimental

    JPC-3210 is a potent antimalarial agent. It is an erythrocytic schizonticide with potent in vitro antimalarial activity against multidrug-resistant Plasmodium falciparum lines, low cytotoxicity, potent in vivo efficacy against murine mal...

    Categories: Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP3A Inhibitors
  6. Drug

    Pralsetinib

    go.drugbank.com/drugs/DB15822
    ApprovedInvestigational

    Pralsetinib, similar to the previously approved selpercatinib, is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes. Enhanced RET (Rearranged during transfection) oncogene expres...

    Categories: P-glycoprotein inhibitors, P-glycoprotein substrates
  7. Drug

    Methacetin methoxy-C-13

    go.drugbank.com/drugs/DB15885
    Investigational

    Synonyms: p-Acetanisidine C-13Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 Substrates
  8. Drug

    Lumasiran

    go.drugbank.com/drugs/DB15935
    ApprovedInvestigational

    Lumasiran is a small interfering RNA used in the treatment of primary hyperoxaluria type 1 (PH1). This condition, caused by a deficiency in the enzyme alanine-glyoxylate aminotransferase, leads to an accumulation of oxalate, causing calc...

    Categories: Cytochrome P-450 CYP2C8 Inhibitors, Cytochrome P-450 Enzyme Inhibitors
  9. Drug

    Bicyclol

    go.drugbank.com/drugs/DB16014
    Investigational

    Bicyclol is under investigation in clinical trial NCT02944552 (The Multi Center, Randomized, Double-blind, Positive Controlled Study of Bicyclol in the Treatment of Acute DILI).

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  10. Drug

    Ensifentrine

    go.drugbank.com/drugs/DB16157
    ApprovedInvestigational

    Ensifentrine is a first-in-class, selective dual inhibitor of the phosphodiesterase 3 (PDE3) and phosphodiesterase 4 (PDE4) enzymes. On June 26, 2024, the FDA announced the approval of an inhaled product of ensifentrine for the treatment...

    Synonyms: N-(2-((2E)-9,10-DIMETOXI-4-OXO-2-((2,4,6-TRIMETILFENIL)IMINO)-6,7-DIHIDRO-2H-PIRIMIDO(6,1-A)ISOQUINOLEIN-3(4H)-IL)ETIL)UREACategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C9 Substrates